Integrated Discovery Engine
Leveraging our deep industry experience and knowledge, we have built our Integrated Discovery Engine, which combines our extensive capabilities across cancer biology and medicinal chemistry. We utilize this discovery engine to identify targets and develop small molecules that we believe could have potentially differentiated product profiles. In five years since inception, our advanced approach has allowed us to successfully clear three INDs with the FDA, with a fourth IND submitted in March 2020 and a fifth expected in 2021. This approach for synthesizing compounds, from identification to IND, is significantly shorter than the average large pharmaceutical institution. Furthermore, we believe our Integrated Discovery Engine has the potential to generate product candidates addressing a wide range of additional therapeutic areas.